Financial Performance - The company's operating revenue for 2017 was CNY 2,976,771,644.51, representing an increase of 8.77% compared to CNY 2,736,697,077.39 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 1,863,471,361.46, reflecting an increase of 11.82% from CNY 1,666,491,361.24 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,708,064,399.15, up by 9.66% from CNY 1,557,610,982.16 in 2016[18]. - The basic earnings per share for 2017 was CNY 1.60, a 10.34% increase from CNY 1.45 in 2016[18]. - The total assets at the end of 2017 amounted to CNY 21,854,589,523.85, which is a 7.44% increase from CNY 20,340,503,252.70 at the end of 2016[18]. - The net assets attributable to shareholders at the end of 2017 were CNY 20,299,720,068.13, an increase of 8.91% from CNY 18,639,145,493.59 in 2016[18]. - The net cash flow from operating activities for 2017 was CNY 256,485,969.89, a decrease of 23.16% compared to CNY 333,812,958.37 in 2016[18]. - The weighted average return on net assets for 2017 was 9.59%, slightly up from 9.43% in 2016[18]. Revenue and Growth - In Q1 2017, the company reported operating revenue of ¥501.20 million, which increased to ¥989.54 million by Q4 2017, reflecting a growth of 97.0% over the year[22]. - The company achieved operating revenue of CNY 2,976.77 million, an increase of CNY 240.07 million, or 8.77% compared to the same period last year[34]. - The pharmaceutical segment contributed ¥2,888,055,937.04, accounting for 97.02% of total revenue, with a year-on-year growth of 8.45%[44]. - The company reported a total of 3,351 employees by the end of 2017, with 1,718 holding a college degree or higher[40]. Investments and Assets - The company achieved a 11.61% increase in long-term equity investments due to additional shares acquired in Guangfa Securities and its profitability[27]. - The company’s overseas investment in Hong Kong amounted to ¥507.07 million, contributing to its overall asset growth[29]. - The company holds 1,252,297,867 shares of Guangfa Securities, accounting for 16.93% of its total share capital[36]. - The total investment amount for the reporting period was CNY 954,478,031.40, a decrease of 32.80% from the previous year[70]. - The total investment income amounted to CNY 1,481,178,161.93, accounting for 76.62% of total profit, mainly from investments in Guangfa Securities[63]. Research and Development - The company has maintained a strong focus on R&D, enhancing its product competitiveness and operational efficiency, which is crucial in the pharmaceutical industry[25]. - Research and development investment amounted to 94,130,909.05 CNY, which is 3.16% of total operating revenue, showing a slight decrease from 3.31% in 2016[57]. - Jilin Aodong is investing 100 million CNY in R&D for new drug development, focusing on innovative therapies[180]. Dividend Policy - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) to all shareholders[6]. - In 2017, the total cash dividend amounted to 348,830,988.60 yuan, representing 18.72% of the net profit attributable to ordinary shareholders, which was 1,863,471,361.46 yuan[102]. - The company has maintained a consistent cash dividend policy over the past three years, with clear standards and procedures in place[101]. Corporate Governance - The company appointed Zhongzhun Accounting Firm as its auditor for the 2017 financial report, with an audit fee of 700,000 CNY[111]. - The independent directors have fulfilled their responsibilities in the decision-making process regarding the cash dividend policy[100]. - The governance structure complies with the regulatory standards set by the China Securities Regulatory Commission[200]. Social Responsibility - The company emphasizes social responsibility and aims for harmonious development with the environment and society[139]. - The company allocated RMB 3 million for poverty alleviation efforts, including a donation of RMB 2 million to the "Poverty Alleviation" project and the establishment of a goat breeding farm[143][145]. - A total of 1,261 registered impoverished individuals were helped to escape poverty through various initiatives[143]. Employee Relations - The company has implemented a transparent and fair employee selection mechanism, enhancing team cohesion and competitiveness[40]. - The remuneration for the chairman, Li Xiulin, was 3.89 million yuan, while the general manager, Guo Shuqin, received 2.01 million yuan[190]. - The company follows a performance-based salary system, with remuneration determined by job position and company performance[189]. Market Strategy - The company is adapting its marketing strategies to align with new healthcare policies, aiming to optimize its sales structure and enhance product positioning[90]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2020[180]. - The company is implementing new digital marketing strategies, projected to increase online sales by 30% in 2018[180].

Financial Performance - Operating revenue for the reporting period was ¥761.60 million, representing a year-on-year growth of 19.37%[8] - Net profit attributable to shareholders was ¥458.35 million, up 3.37% from the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥424.22 million, a slight increase of 0.45%[8] - Basic earnings per share for the reporting period were ¥0.3942, reflecting a growth of 2.36%[8] - The weighted average return on net assets was 2.37%, a decrease of 0.16% compared to the previous year[8] - The net cash flow from operating activities for the year-to-date was ¥144.16 million, down 28.17%[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 86,993[13] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.66% of the shares, amounting to 309,940,049 shares[13] Non-Recurring Items - Non-recurring gains and losses totaled ¥92.29 million for the year-to-date, after accounting for tax and minority interests[10] Asset and Liability Changes - Total assets at the end of the reporting period reached ¥21.64 billion, an increase of 6.40% compared to the end of the previous year[8] - The balance of financial assets measured at fair value decreased by 44.31% compared to the beginning of the year, mainly due to a reduction in short-term stock investments[17] - Accounts receivable increased by 65.07% compared to the beginning of the year, primarily due to an increase in receivables from pharmaceutical sales[17] - Prepayments increased by 216.27% compared to the beginning of the year, mainly due to an increase in advance payments for raw materials[17] - The balance of short-term borrowings decreased by 92.58% compared to the beginning of the year, mainly due to repayments by a subsidiary[17] - The company’s total liabilities decreased significantly, with employee compensation liabilities down by 72.62% compared to the beginning of the year[17] Investment Activities - The net cash flow from investing activities decreased by 55.96% compared to the same period last year, primarily due to an increase in cash paid for investments[19] - The total investment cost for securities held by the company amounts to ¥228,924,667.77, with a fair value change loss of ¥2,137,419.37 during the reporting period[26] - The company reported a fair value of ¥185,877,205.71 at the beginning of the period, and the ending book value is ¥241,908,513.74[26] - The company holds a significant investment in Haitong Securities (06837.HK) with a fair value of ¥81,393,941.00, reflecting a loss of ¥5,502,427.05 during the period[26] - The investment in China Ping An (601318) shows a fair value of ¥46,036,000.00, with a profit of ¥36,401,676.47 reported[26] - The total fair value of available-for-sale financial assets is reported at ¥865,576,120.48, with a total initial investment cost of ¥735,196,658.00[27] Social Responsibility and Community Engagement - The company has invested ¥200,000 in poverty alleviation projects, focusing on agricultural and forestry industry development[34] - The company plans to continue its poverty alleviation efforts by promoting related farming and breeding industries, aiming for precise poverty alleviation[35] - The company actively engages in social responsibility initiatives, particularly in poverty alleviation, creating job opportunities in impoverished areas[33] Other Financial Information - Other comprehensive income increased by 54.32% compared to the beginning of the year, attributed to gains from an associated company[18] - The company’s tax expenses increased by 52.25% compared to the same period last year, due to adjustments in tax accounting[18] - The company has no derivative investments during the reporting period[29] - There are no violations regarding external guarantees or non-operational fund occupation by major shareholders[31][32]

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 1,225,632,600.83, representing a 0.72% increase compared to CNY 1,216,930,561.84 in the same period last year[19]. - Net profit attributable to shareholders was CNY 911,231,777.09, an increase of 8.70% from CNY 838,262,901.71 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 853,073,621.82, up 2.93% from CNY 828,781,689.14 in the previous year[19]. - Basic and diluted earnings per share increased by 8.33% to CNY 0.78, compared to CNY 0.72 in the previous year[19]. - The company's revenue for the period was CNY 1,225.63 million, reflecting a year-on-year increase of CNY 8.70 million or 0.72%[37]. - The company's total assets reached CNY 20,971.16 million, an increase of CNY 630.65 million or 3.10% compared to the beginning of the year[37]. - The weighted average return on equity was 4.78%, slightly down from 4.80% in the previous year[19]. - The company's total assets increased to CNY 18,654,707,667.47, compared to CNY 18,026,077,434.60 in the previous period[130]. - Earnings per share (EPS) for the period was CNY 0.78, an increase from CNY 0.72 in the same period last year[132]. - The company reported a significant increase in long-term equity investments, rising to CNY 13,809,790,881.87 from CNY 13,451,099,425.55, an increase of approximately 2.7%[124]. Cash Flow and Investments - The net cash flow from operating activities decreased by 41.81% to CNY 73,429,196.85, down from CNY 126,197,102.81 in the same period last year[19]. - Cash inflow from investment activities reached CNY 5,625,435,856.44, significantly up from CNY 2,750,526,988.80, marking a 104.3% increase[138]. - Cash outflow from financing activities was CNY 873,815,059.23, down from CNY 1,487,134,929.56, indicating a 41.2% reduction[139]. - The ending balance of cash and cash equivalents was CNY 1,156,199,229.89, up from CNY 640,124,939.86[139]. - The company invested ¥69,103,706.46 during the reporting period, a decrease of 33.05% compared to the previous year[53]. - The company has invested approximately ¥2.7 billion in 10 projects across various fields including biopharmaceuticals and medical devices[43]. Assets and Liabilities - Total liabilities decreased to CNY 1,355,317,897.23 from CNY 1,466,468,740.58, a reduction of approximately 7.6%[125]. - Shareholders' equity increased to CNY 19,615,840,333.38 from CNY 18,874,034,512.12, reflecting a growth of about 3.9%[125]. - The asset-liability ratio stands at 6.46%, indicating a strong financial position[37]. - The total financial assets at the end of the period were ¥1,091,408,185.42, with significant transactions including purchases of ¥5,516,736,260.42 and sales of ¥5,553,509,210.38[50]. Dividends and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company distributed a cash dividend of 3.00 CNY per 10 shares (including tax) and issued 3 bonus shares per 10 shares to all shareholders based on a total of 894,438,433 shares[79]. - The total number of ordinary shareholders at the end of the reporting period was 88,798, with the largest shareholder holding 26.66% of the shares[108]. - The company’s largest shareholder, Dunhua Jincheng Industrial Co., Ltd., increased its holdings by 71,524,627 shares during the reporting period[108]. Corporate Governance and Management - The company held a board meeting on June 23, 2017, to approve the nomination of candidates for the ninth board of directors and the supervisory board[97]. - The company’s board of directors and supervisory board were re-elected during the first extraordinary general meeting held on July 17, 2017[117]. - The company appointed Guo Shuqin as the general manager and Zhang Shuyuan as the CFO during the first board meeting of the ninth board of directors[99]. - The company approved an employee stock ownership plan in July 2016[78]. Market and Operational Strategy - The company is actively exploring new product development and market expansion in health food and agriculture sectors[27]. - The company is focused on the production of various pharmaceutical products, including traditional Chinese medicine and health food, which aligns with market demand[63]. - The company emphasizes a market-oriented approach, focusing on major and multiple product groups for stable development[67]. - The company is engaged in various sectors, including pharmaceutical manufacturing and research, which supports its growth strategy[154]. Social Responsibility and Community Engagement - The company donated 2 million CNY to the charity fund of Taonan City for poverty alleviation projects during the reporting period[93]. - The company plans to continue its poverty alleviation efforts through industrial development, financial assistance, and participation in social charity activities[96]. Compliance and Reporting - The half-year financial report has not been audited[74]. - The financial report was approved by the board on August 25, 2017, and disclosed on August 26, 2017, ensuring transparency in financial reporting[154]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position and operating results[160].

Financial Performance - The company's operating revenue for Q1 2017 was ¥501,196,830.07, a decrease of 11.73% compared to ¥567,773,907.19 in the same period last year[8] - Net profit attributable to shareholders increased by 15.12% to ¥418,375,965.01 from ¥363,410,249.92 year-on-year[8] - Basic and diluted earnings per share rose by 14.63% to ¥0.47 from ¥0.41 in the same period last year[8] - Total assets at the end of the reporting period were ¥20,989,757,399.24, reflecting a 3.19% increase from ¥20,340,503,252.70 at the end of the previous year[8] - Net assets attributable to shareholders increased by 3.17% to ¥19,229,237,005.98 from ¥18,639,145,493.59 year-on-year[8] Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥11,584,483.10, a 176.62% increase from a negative cash flow of ¥15,118,732.74 in the previous year[8] - The net cash flow from operating activities increased by 176.62% compared to the same period last year, primarily due to increased cash receipts from drug sales[16] - The net cash flow from investing activities increased by 79.83% compared to the same period last year, mainly due to an increase in cash received from investment recoveries[17] - The net cash flow from financing activities increased by 119.86% compared to the same period last year, primarily due to a decrease in cash paid for repaying short-term loans[17] Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥26,824,137.45 for the period[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,388[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 26.66% of the shares, amounting to 238,415,422 shares[11] Expenses and Income - Tax expenses increased by 33.63% compared to the same period last year, mainly due to the adjustment of property tax and land use tax to the "taxes and surcharges" account[15] - Financial expenses decreased by 111.68% compared to the same period last year, mainly due to a reduction in bank loan interest payments[15] - Asset impairment losses decreased by 56.81% compared to the same period last year, mainly due to a decrease in bad debt losses recognized[15] - Operating income from non-operating activities increased by 64.69% compared to the same period last year, mainly due to an increase in government subsidies recognized in the current period[15] Investments - The total investment in securities at the end of the reporting period amounted to CNY 532,072,403.04, with a report period profit of CNY 15,342,290.25[20] - The company held 64,308,554 shares at the end of the reporting period, an increase from 55,078,845 shares at the beginning[20] - The investment in China Ping An increased from 3,432,200 shares (0.02%) to 4,772,000 shares (0.03%) during the reporting period[20] - The investment in CITIC Securities rose from 4,950,000 shares (0.04%) to 11,183,500 shares (0.09%)[20] - The investment in China Reinsurance remained stable at 7,123,000 shares (0.02%) throughout the reporting period[20] - The total value of other securities investments at the end of the reporting period was CNY 22,921,529.74, with a profit of CNY 1,005,493.96[20] Other Information - The company did not engage in any repurchase agreements during the reporting period[12] - The company did not engage in any derivative investments during the reporting period[21] - There were no violations regarding external guarantees during the reporting period[23] - The company reported no non-operating fund occupation by controlling shareholders or related parties[24] - The company conducted a communication session regarding its production and operation status during the reporting period[22] - The ending balance of prepaid expenses increased by 112.81% compared to the beginning of the year, mainly due to the increase in prepayments for raw material purchases[15] - The fair value change income increased by 140.50% compared to the same period last year, mainly due to the impact of fair value changes in trading financial assets such as stocks and funds[15] - Other comprehensive income attributable to owners of the parent company increased by 156.06% compared to the same period last year, mainly due to the increase in other comprehensive income of the associated company Guangfa Securities[15]

Financial Performance - The company's operating revenue for 2016 was CNY 2,736,697,077.39, representing a 17.22% increase compared to CNY 2,334,760,837.13 in 2015[17]. - The net profit attributable to shareholders decreased by 35.75% to CNY 1,666,491,361.24 from CNY 2,593,589,316.67 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 1,557,610,982.16, down 37.22% from CNY 2,480,906,545.47 in 2015[17]. - The net cash flow from operating activities was CNY 333,812,958.37, a decrease of 13.97% compared to CNY 388,032,364.72 in 2015[17]. - Basic earnings per share fell by 34.83% to CNY 1.89 from CNY 2.90 in the previous year[17]. - The company reported a weighted average return on equity of 9.43%, down from 17.33% in 2015, reflecting a decrease of 7.90%[17]. - Quarterly operating revenue for Q4 2016 was CNY 881,754,458.59, contributing to the overall annual revenue growth[20]. - The net profit attributable to shareholders was CNY 363,410,249.92, a decrease from CNY 474,852,651.79 in 2015, representing a decline of approximately 23.5%[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 365,430,866.85, down from CNY 463,350,822.29 in 2015, indicating a decrease of about 21.1%[21]. - The net cash flow from operating activities was negative CNY 15,118,732.74, contrasting with a positive CNY 141,315,835.55 in 2015[21]. Assets and Investments - Total assets at the end of 2016 were CNY 20,340,503,252.70, an increase of 2.55% from CNY 19,834,016,266.66 at the end of 2015[17]. - The net assets attributable to shareholders increased by 7.25% to CNY 18,639,145,493.59 from CNY 17,378,771,619.39 in 2015[17]. - Long-term equity investments increased by 2.15% compared to the beginning of the year, primarily due to additional shares acquired in Guangfa Securities[27]. - Fixed assets grew by 18.44% year-on-year, mainly due to the completion of construction projects in subsidiaries[27]. - The company’s total revenue from the food segment was ¥58,006,717.69, reflecting an 8.54% increase from ¥53,442,359.35 in 2015[44]. - The company reported a total investment of ¥1,420,415,336.37 during the reporting period, a decrease of 20.35% compared to ¥1,783,395,983.21 in the same period last year[65]. - The company’s total current assets as of December 31, 2016, amounted to CNY 3,239,531,829.74, an increase from CNY 3,156,822,361.18 at the beginning of the year, reflecting a growth of approximately 2.6%[200]. - The company's total non-current assets reached CNY 13,451,099,425.55, up from CNY 13,167,483,356.03, indicating an increase of approximately 2.1%[200]. Dividends and Shareholder Information - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) and issue 3 bonus shares per 10 shares (including tax) based on a total of 894,438,433 shares[6]. - The cash dividend amount for 2016 was CNY 268,331,529.90, representing 16.10% of the net profit attributable to ordinary shareholders, which was CNY 1,666,491,361.24[100]. - In 2015, the cash dividend was CNY 262,388,607.00, accounting for 10.12% of the net profit of CNY 2,593,589,316.67[100]. - The total number of shareholders at the end of the reporting period was 94,273, an increase from 86,705 at the end of the previous month[145]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 170,687,108 shares, representing 26.66% of total shares[146]. - The company’s total share capital remains at 894,438,433 shares, with 92.21% being unrestricted shares[142]. Corporate Governance and Compliance - The company has a strong commitment to corporate governance and transparency in its operations[160]. - The company has maintained stable leadership with no changes in the board of directors or senior management during the reporting period[156]. - The company has established a scientific salary system based on job positions and company performance[166]. - The company emphasizes training to enhance core competitiveness and improve employee skills through various training methods[167]. - The company has implemented a strict insider information management system to prevent the leakage of non-public significant information[174]. - The audit report issued by the accounting firm confirmed a standard unqualified opinion on the financial statements for the year ended December 31, 2016[193]. - The company has established a comprehensive compensation management system and performance evaluation system for senior management[186]. Research and Development - The company is advancing the research and development of new products, including "Aodong Brand Zao Ren Yi Shen Oral Liquid" and "Injection of Hydrochloride Boanmycin" for additional indications[87]. - Research and development expenses amounted to CNY 90,556,593.18 in 2016, a decrease of 3.88% from CNY 94,209,378.30 in 2015, representing 3.31% of total revenue[55]. - The company emphasizes a comprehensive quality control system to ensure the highest standards in production, focusing on five key aspects: people, machines, materials, methods, and environment[87]. Social Responsibility and Community Engagement - The company allocated a total of RMB 300,000 for targeted poverty alleviation efforts in 2016[130]. - A total of 384 registered impoverished individuals were lifted out of poverty through the company's initiatives[131]. - The company invested RMB 11.39 million in agricultural development projects aimed at poverty alleviation, benefiting 93 individuals[131]. - The company provided RMB 8.17 million in financial support for 94 impoverished students[131]. - The company’s environmental protection expenditure amounted to RMB 4.0097 million in 2016[136]. - The company made social welfare donations totaling RMB 1.4893 million[136]. Market Strategy and Future Outlook - The company plans to enhance production automation and smart construction in its pharmaceutical subsidiaries to improve overall competitiveness[87]. - The company will continue to focus on internal growth while exploring acquisition opportunities to achieve external growth and enhance efficiency[90]. - The company has shifted focus away from the sanitary products sector, leading to a 100% decrease in sales and procurement in that category[47]. - The company aims to distribute cash dividends of 3.00 yuan per 10 shares, totaling approximately 268.33 million yuan, which represents 50% of the total profit distribution[98].

[Important Notice](index=2&type=section&id=Important%20Notice) The company ensures the truthfulness, accuracy, and completeness of this quarterly report [Board of Directors and Senior Management Statement](index=2&type=section&id=Board%20of%20Directors%20and%20Senior%20Management%20Statement) The company's board, supervisory board, and senior management guarantee the report's accuracy and assume legal responsibility - The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content, and assume corresponding legal responsibilities[4](index=4&type=chunk) - The company's Chairman, General Manager, Chief Financial Officer, and Head of Accounting guarantee the truthfulness, accuracy, and completeness of the financial statements[5](index=5&type=chunk) [Key Financial Data and Shareholder Changes](index=3&type=section&id=Key%20Financial%20Data%20and%20Shareholder%20Changes) This section presents the company's key financial performance indicators and shareholder structure [Key Accounting Data and Financial Indicators](index=3&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In the first three quarters of 2016, operating revenue increased by 12.65%, but net profit attributable to shareholders decreased by 36.49% Key Financial Indicators for Q3 2016 | Indicator | End of Reporting Period/Year-to-Date | Change | End of Prior Year/Prior Period | | :--- | :--- | :--- | :--- | | **Balance Sheet Items** | | | | | Total Assets (Yuan) | 19,328,496,425.71 | -2.55% | 19,834,016,266.66 | | Net Assets Attributable to Parent Company Shareholders (Yuan) | 17,638,390,664.01 | 1.49% | 17,378,771,619.39 | | **Income Statement Items** | | | | | Operating Revenue (Yuan) | 1,854,942,618.80 | 12.65% | - | | Net Profit Attributable to Parent Company Shareholders (Yuan) | 1,281,673,315.16 | -36.49% | - | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-recurring Items) (Yuan) | 1,251,080,564.68 | -37.06% | - | | Basic Earnings Per Share (Yuan/share) | 1.4472 | -35.86% | - | | Weighted Average Return on Net Assets | 7.31% | -6.45% | - | | **Cash Flow Statement Items** | | | | | Net Cash Flow from Operating Activities (Yuan) | 200,698,106.39 | -4.25% | - | Non-recurring Gains and Losses and Amounts | Item | Amount Year-to-Date (Yuan) | Explanation | | :--- | :--- | :--- | | Gains and losses on disposal of non-current assets | -531,549.23 | | | Government grants recognized in current profit or loss | 26,429,493.76 | | | Gains from investment costs of acquiring subsidiaries, etc., being less than the fair value of identifiable net assets of the investee | 125,191.81 | | | Gains and losses from changes in fair value of financial assets held for trading and investment income | 11,224,463.04 | | | Other non-operating income and expenses | -1,846,281.48 | | | Less: Income tax impact | 3,681,711.50 | | | Less: Impact of minority interests (after tax) | 1,126,855.92 | | | **Total** | **30,592,750.48** | -- | [Shareholder Information](index=3&type=section&id=Shareholder%20Information) As of the reporting period end, the company had 88,662 common shareholders, with Dunhua Jincheng Industrial as the largest shareholder - As of the end of the reporting period, the total number of common shareholders was **88,662**[11](index=11&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Percentage | Number of Shares Held (shares) | | :--- | :--- | :--- | :--- | | Dunhua Jincheng Industrial Co., Ltd. | Domestic Non-State-Owned Legal Person | 25.92% | 231,796,333 | | GF Securities Co., Ltd. | Domestic Non-State-Owned Legal Person | 3.67% | 32,824,000 | | Jilin Aodong Pharmaceutical Group Co., Ltd. Repurchase Special Securities Account | Domestic Non-State-Owned Legal Person | 2.21% | 19,809,743 | | Central Huijin Asset Management Co., Ltd. | State-Owned Legal Person | 1.50% | 13,430,400 | | China Securities Finance Corporation Limited | Other | 1.23% | 11,043,025 | | Yanbian State-Owned Assets Management Co., Ltd. | State-Owned Legal Person | 0.95% | 8,455,554 | | Ding Jinxiang | Domestic Natural Person | 0.83% | 7,421,160 | | Bank of China - China Asset Management New Economy Mixed Fund | Domestic Non-State-Owned Legal Person | 0.51% | 4,591,337 | | National Social Security Fund Council 602 Portfolio | Domestic Non-State-Owned Legal Person | 0.37% | 3,274,496 | | Wen Peilin | Domestic Natural Person | 0.31% | 2,805,337 | [Important Matters](index=5&type=section&id=Important%20Matters) This section details significant changes in financial statements, commitments, and other key events [Analysis of Financial Statement Item Changes](index=5&type=section&id=Analysis%20of%20Financial%20Statement%20Item%20Changes) Significant changes in financial statement items include a 48.02% decrease in monetary funds and a 99.24% decrease in short-term borrowings - **Balance Sheet Major Changes**: - **Monetary Funds**: Decreased by **48.02%** at period-end compared to year-start, primarily due to repayment of short-term borrowings and share repurchases[14](index=14&type=chunk) - **Accounts Receivable**: Increased by **73.75%** at period-end compared to year-start, mainly due to increased receivables from drug sales[14](index=14&type=chunk) - **Short-term Borrowings**: Decreased by **99.24%** at period-end compared to year-start, primarily due to repayment of short-term borrowings[14](index=14&type=chunk) - **Treasury Stock**: Significantly increased at period-end, primarily due to the repurchase of company shares[14](index=14&type=chunk) - **Other Comprehensive Income**: Decreased by **40.78%** at period-end compared to year-start, mainly due to a decrease in other comprehensive income of associate GF Securities, adjusted by equity method[14](index=14&type=chunk) - **Income Statement Major Changes**: - **Investment Income**: Decreased by **43.46%** in the current period compared to the same period last year, primarily due to reduced investment income from GF Securities Co., Ltd[16](index=16&type=chunk) - **Net Profit Attributable to Parent Company Owners**: Decreased by **36.49%** in the current period compared to the same period last year, primarily due to the same reason as the decrease in investment income[16](index=16&type=chunk) - **Net Other Comprehensive Income Attributable to Parent Company Owners (After Tax)**: Decreased by **213.21%** in the current period compared to the same period last year, primarily due to a decrease in other comprehensive income of associate GF Securities[16](index=16&type=chunk) - **Cash Flow Statement Major Changes**: - **Net Cash Flow from Investing Activities**: Increased by **168.42%** in the current period compared to the same period last year, primarily due to increased cash received from investment income and decreased cash paid for external investments[16](index=16&type=chunk) - **Net Cash Flow from Financing Activities**: Decreased by **267.69%** in the current period compared to the same period last year, primarily due to increased cash paid for share repurchases and loan repayments[16](index=16&type=chunk) [Commitments](index=6&type=section&id=Commitments) The major shareholder's commitment regarding restricted share sales from equity division reform is ongoing until August 4, 2020 - Major shareholder Dunhua Jincheng Industrial Co., Ltd. committed during the equity division reform that the number of non-tradable shares it holds, once listed, will not exceed **2%** of Jilin Aodong's total share capital annually when sold through stock exchange listings[17](index=17&type=chunk) - The restricted shares under this equity division reform commitment will not be fully tradable until **August 4, 2020**, at which point the commitment will be fulfilled[19](index=19&type=chunk) [Securities Investment](index=8&type=section&id=Securities%20Investment) As of the reporting period end, the company's securities investments had a book value of approximately 227 million Yuan, incurring a loss of 6.52 million Yuan Securities Investment Holdings Details | Security Type | Security Name | Shares Held at Period-End | Book Value at Period-End (Yuan) | Profit/Loss for Reporting Period (Yuan) | | :--- | :--- | :--- | :--- | :--- | | Stock | China Ping An | 3,316,700.00 | 113,298,472.00 | -1,066,895.21 | | Stock | Haitong Securities | 4,703,600.00 | 53,131,519.42 | -787,480.60 | | Stock | CITIC Securities | 976,000.00 | 13,831,448.61 | -240,981.54 | | Fund | GF Core Selection | 3,304,808.45 | 9,851,633.99 | -627,913.60 | | Fund | GF Strategy Selection | 3,418,709.61 | 6,334,868.91 | -967,836.69 | | Other | - | - | 20,594,269.36 | -2,631,399.08 | | **Total** | **--** | **39,712,326.58** | **226,940,980.34** | **-6,522,853.43** | [Investor Relations Activities](index=8&type=section&id=Investor%20Relations%20Activities) During Q3 2016, the company engaged with individual investors via phone regarding its operations - The company communicated with individual investors via telephone regarding its production and operational status during the reporting period[23](index=23&type=chunk) [Other Important Matters](index=7&type=section&id=Other%20Important%20Matters) The company has not provided a 2016 performance forecast and reports no derivative investments or illegal guarantees - The company has not provided a forecast for its **2016** operating performance[20](index=20&type=chunk) - The company had no derivative investments, illegal external guarantees, or non-operating funds occupied by controlling shareholders or their related parties during the reporting period[22](index=22&type=chunk)[24](index=24&type=chunk)[25](index=25&type=chunk)

Financial Performance - The company's operating revenue for the reporting period was CNY 1,216,930,561.84, representing a 6.88% increase compared to CNY 1,138,644,975.94 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 49.50% to CNY 838,262,901.71 from CNY 1,659,945,613.45 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 828,781,689.14, down 48.81% from CNY 1,619,176,395.26 year-on-year[17]. - Basic earnings per share decreased by 49.46% to CNY 0.94 from CNY 1.86 in the previous year[17]. - The company reported a significant decrease in total profit to ¥874,109,091.64 from ¥1,693,285,757.60, a decline of 48.3%[116]. - The investment income decreased significantly to ¥652,097,536.56 from ¥1,476,223,796.70, a drop of 55.8%[116]. - The gross profit margin for the overall business was 70.63%, a decrease of 12.63% compared to the previous year[38]. Cash Flow and Assets - The net cash flow from operating activities increased by 28.67% to CNY 126,197,102.81, compared to CNY 98,076,678.98 in the same period last year[17]. - The company's cash and cash equivalents decreased to ¥640,124,939.86 from ¥1,849,884,928.42, representing a decline of approximately 65.4%[108]. - Total assets at the end of the reporting period were CNY 19,616,901,093.62, a decrease of 1.09% from CNY 19,834,016,266.66 at the end of the previous year[17]. - The total current assets amounted to ¥3,321,699,227.22, up from ¥3,156,822,361.18, indicating an increase of approximately 5.2%[108]. - The total cash outflow from investing activities was 3,209,055,537.00 CNY, compared to 4,098,865,739.88 CNY in the previous period, indicating a decrease of about 21.6%[123]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company distributed a cash dividend of RMB 3 per 10 shares to shareholders based on the total share capital of 894,438,433 shares as of the end of 2015[53]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 25.92% of the shares, amounting to 231,796,333 shares[92]. - The company has a total of 894,438,433 shares, with 90.22% being unrestricted shares[92]. Investments and Subsidiaries - The company holds a 16.70% stake in Guangfa Securities, with a book value of ¥12,366,595,558.72 and a reported gain of ¥672,760,008.95 during the reporting period[42]. - The subsidiary Jilin Aodong Yanyuan Pharmaceutical Co., Ltd. reported a net profit of RMB 33.47 million on revenue of RMB 392.39 million[52]. - The company established several investment funds in collaboration with Guangfa Securities to enhance resource and capital interaction[31]. Operational Changes and Management - The company is focusing on improving product quality management and has established a comprehensive supplier database to ensure quality control[26]. - The company has initiated secondary development projects for existing products, leveraging partnerships with academic institutions for quality standard enhancements[26]. - The company’s management structure promotes a decentralized governance model, enhancing operational efficiency and stability[40]. Compliance and Governance - The company has established a complete internal control system to ensure compliance and asset security[60]. - There were no significant litigation or arbitration matters during the reporting period[61]. - The company confirmed that there are no significant issues regarding its ability to continue as a going concern for the next 12 months[139]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect true and complete financial conditions[141]. - The company uses Renminbi as its functional currency for domestic operations, while foreign subsidiaries use their respective local currencies[144]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, such as significant financial difficulties of the issuer or debtor[171].

Financial Performance - The company's operating revenue for Q1 2016 was ¥567,773,907.19, representing an increase of 8.17% compared to ¥524,888,874.41 in the same period last year[7]. - The net profit attributable to shareholders decreased by 38.07% to ¥363,410,249.92 from ¥586,843,767.58 year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 35.77% to ¥365,430,866.85 compared to ¥568,956,135.09 in the previous year[7]. - Basic and diluted earnings per share decreased by 37.88% to ¥0.41 from ¥0.66 year-on-year[7]. - The weighted average return on net assets dropped to 2.09%, down by 2.43% from 4.52% in the previous year[7]. - Net profit attributable to the parent company decreased by 38.07% year-on-year, mainly due to a decrease in net profit from Guangfa Securities[16]. - Investment income decreased by 43.83% year-on-year, primarily due to a decrease in net profit attributable to the parent company from Guangfa Securities[15]. - Other comprehensive income after tax decreased by 255.82% year-on-year, mainly due to a reduction in other comprehensive income from Guangfa Securities[16]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥15,118,732.74, a significant decline of 2,071.61% from -¥696,199.93 in the same period last year[7]. - Cash flow from operating activities decreased by 2,071.61% year-on-year, mainly due to a reduction in business receivables and increased cash payments for raw materials[16]. - Cash flow from investing activities decreased by 69.45% year-on-year, primarily due to increased investments in Guangfa Securities[16]. - Total assets at the end of the reporting period were ¥19,934,404,787.52, a slight increase of 0.51% from ¥19,834,016,266.66 at the end of the previous year[7]. - The net assets attributable to shareholders increased by 0.33% to ¥17,435,893,869.74 from ¥17,378,771,619.39 at the end of the previous year[7]. - Other non-current assets increased by 109.52% compared to the beginning of the year, mainly due to increased payments for projects and equipment[14]. - Deferred income tax liabilities decreased by 38.40% compared to the beginning of the year, mainly due to a reduction in deferred tax liabilities from available-for-sale financial assets[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 99,507[10]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., held 25.92% of the shares, amounting to 231,796,333 shares, with 186,120,000 shares pledged[10]. - The total number of shares held at the end of the period is 32,036,707.58, with a corresponding book value of ¥158,053,100.41[20]. Investments and Market Activity - The total investment in securities amounts to ¥156,252,858.61, with a total loss of ¥14,228,245.89 during the reporting period[20]. - The company holds 1,750,000 shares of China Ping An, with an initial investment of ¥67,203,420.36, resulting in a loss of ¥7,332,500.00[20]. - The investment in the fund "Guangfa Core Select" is valued at ¥8,929,592.43, with a loss of ¥1,549,955.16 during the reporting period[20]. - The company has no derivative investments during the reporting period[21]. Compliance and Communication - There were no violations regarding external guarantees during the reporting period[23]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24]. - The company engaged in communication activities regarding its production and operation from January 1 to March 31, 2016[22]. - The company has not provided any forecasts for the first half of 2016[20].

Financial Performance - The company's operating revenue for 2015 was CNY 2,334,760,837.13, representing a 4.23% increase compared to CNY 2,240,099,344.17 in 2014[17]. - The net profit attributable to shareholders for 2015 was CNY 2,593,589,316.67, an increase of 83.85% from CNY 1,410,692,545.80 in 2014[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,480,906,545.47, up 86.27% from CNY 1,331,918,290.35 in 2014[17]. - The net cash flow from operating activities for 2015 was CNY 388,032,364.72, a 34.35% increase from CNY 288,827,750.65 in 2014[17]. - The total assets at the end of 2015 were CNY 19,834,016,266.66, a 44.04% increase from CNY 13,769,524,682.67 at the end of 2014[17]. - The net assets attributable to shareholders at the end of 2015 were CNY 17,378,771,619.39, reflecting a 38.13% increase from CNY 12,581,242,478.07 at the end of 2014[17]. - The basic earnings per share for 2015 were CNY 2.90, an increase of 83.54% compared to CNY 1.58 in 2014[17]. - The weighted average return on equity for 2015 was 17.33%, up from 11.96% in 2014, an increase of 5.37%[17]. - The company reported a net profit of CNY 3,538,256,637.56 for the year 2015, with a total distributable profit of CNY 10,205,495,407.81 after accounting for statutory reserves and dividends[97]. Revenue Breakdown - The pharmaceutical segment generated CNY 2,245,865,183.91, accounting for 96.19% of total revenue, with a year-on-year growth of 2.66%[45]. - Revenue reached CNY 233,476.08 million, marking a 4.23% increase from the previous year[36]. - The revenue from the food segment increased by 31.49% to CNY 53,442,359.35, compared to CNY 40,644,301.57 in 2014[45]. Investment and Assets - The company's long-term equity investments rose to CNY 13,167,483,356.03, accounting for 66.39% of total assets, an increase of 3.40% from the previous year[65]. - The total investment amount for the reporting period was CNY 1,783,395,983.21, a significant increase of 3,678.01% compared to CNY 47,204,622.18 in the previous year[68]. - The company achieved a return on investment of CNY 22.82 billion from Guangfa Securities, a 116.12% increase year-on-year[36]. - The total assets of Jilin Aodong Pharmaceutical Group Co., Ltd. as of December 31, 2015, amounted to CNY 19.83 billion, an increase from CNY 13.77 billion at the beginning of the year, representing a growth of approximately 44.2%[194]. Cash Flow and Financing - The cash outflow from financing activities increased by 207.83% year-on-year, mainly due to higher cash dividends paid[61]. - The total cash inflow from financing activities was CNY 1,252,440,000.00, a dramatic increase of 2,940.56% compared to CNY 41,191,090.56 in the previous year[61]. - The net cash flow from financing activities increased by 1,411.73% compared to the previous year, mainly due to an increase in short-term loans from subsidiaries[61]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 3 per 10 shares, totaling CNY 26,832,000 based on 894,438,433 shares[6]. - A cash dividend of CNY 3.00 per 10 shares (including tax) was proposed, resulting in a total cash dividend payout of CNY 268,331,529.90, which represents 100% of the profit distribution[97]. - The cash dividend for 2015 accounted for 10.35% of the net profit attributable to ordinary shareholders, compared to 12.68% in 2014 and 8.45% in 2013[98]. Operational Highlights - The company has emphasized employee training and recruitment aligned with corporate values, adding 29 new registered pharmacists during the year[39]. - The company maintains a quality assurance system with a three-tier quality control model, ensuring product safety and reliability[37]. - The company has received multiple approvals for new products, including various traditional Chinese medicine products and health supplements[38]. Strategic Initiatives - The company plans to focus on new drug research and development while enhancing cooperation with research institutions for secondary development of major products[85]. - The company aims to upgrade quality standards for "Small Cow Spleen Extract Injection" and accelerate the secondary development of "Heart and Brain Comfort Capsule" projects[86]. - The company is committed to improving the quality control and traceability of products throughout their lifecycle, which is expected to support sustained growth in the pharmaceutical industry[86]. Corporate Governance - The company has maintained a good integrity status, with no significant legal judgments or large debts due that remain unpaid[109]. - The company has not faced any major lawsuits or arbitration matters during the reporting period[107]. - The company engaged Lixin Accounting Firm for internal control audit services, with a fee of CNY 300,000[105]. Employee and Management Structure - The total number of employees in the company is 4,189, with 25 in the parent company and 4,164 in major subsidiaries[159]. - The company has a professional composition of 1,883 production personnel, 1,323 sales personnel, 342 technical personnel, 118 financial personnel, and 523 administrative personnel[160]. - The remuneration for directors, supervisors, and senior management is determined based on the company's performance and is approved by the shareholders' meeting[158].

Financial Performance - Operating revenue for the current period was CNY 507.97 million, a slight decrease of 0.61% year-on-year[6] - Net profit attributable to shareholders decreased by 4.07% to CNY 358.11 million for the current period[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 3.77% to CNY 368.46 million[6] - Basic earnings per share for the current period was CNY 0.4004, down 4.07% year-on-year[6] - The weighted average return on equity was 2.44%, a decrease of 0.81% compared to the previous year[6] Assets and Liabilities - Total assets increased by 41.12% to CNY 19.43 billion compared to the end of the previous year[6] - Net assets attributable to shareholders increased by 33.04% to CNY 16.74 billion compared to the end of the previous year[6] - Accounts receivable increased by 122.72% compared to the beginning of the year, mainly due to an increase in receivables from pharmaceutical sales[12] - Prepayments increased by 255.63% compared to the beginning of the year, primarily due to increased prepayments for raw material purchases[12] - Short-term borrowings increased by 3220.26% compared to the beginning of the year, including credit borrowings of 500 million yuan from subsidiaries[12] - Other non-current assets increased by 190.99% compared to the beginning of the year, mainly due to increased payments for projects and equipment[12] - Deferred tax liabilities increased by 1565.56% compared to the beginning of the year, mainly due to the recognition of deferred tax liabilities from temporary differences related to available-for-sale financial assets[12] Investment Income - Net profit attributable to the parent company increased by 120.77% compared to the same period last year, mainly due to increased investment income from Guangfa Securities[13] - Investment income increased by 175.85% compared to the same period last year, primarily due to increased investment income from Guangfa Securities[13] - The company holds a 16.57% stake in Guangfa Securities, with an investment income of CNY 1,815,984,951.34 during the reporting period[18] - The company invested CNY 537,330,786.70 to acquire 129,477,298 shares of Jilin Yatai Group, representing a 4.98% ownership[18] - The total initial investment in other listed companies amounts to CNY 1,363,931,879.85, with a total book value of CNY 13,032,767,240.06[18] - The company reported a loss of CNY 1,036,761.91 related to the investment in the American Life Therapy Company (VTL)[18] Cash Flow - The company reported a net cash flow from operating activities of CNY 209.60 million, an increase of 172.59% year-on-year[6] - Cash flow from operating activities increased by 172.59% compared to the same period last year, mainly due to an increase in business receivables and government subsidies[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 87,560[9] - The largest shareholder, Dunhua Jincheng Industry Co., Ltd., held 25.02% of the shares, totaling 223,802,322 shares[9] Other Information - The company does not engage in derivative investments during the reporting period[20] - There are no violations regarding external guarantees during the reporting period[22] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[23] - The company communicated with investors regarding its production and operational status on July 1, 2015[21] - The company anticipates significant changes in cumulative net profit compared to the previous year[16] - The company’s total securities investment at the end of the period is valued at CNY 92,753,724.21, with a loss of CNY 9,522,507.02 during the reporting period[16]